Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

Official Title

An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen (CheckMate 907: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 907)

Summary:

A study to evaluate the safety of Nivolumab in patients with advanced or metastatic non-small cell lung cancer

Trial Description

Primary Outcome:

  • Incidence of high grade (Grades 3-4 and Grade 5) treatment-related adverse events
Secondary Outcome:
  • Progression-free Survival (PFS) as determined by investigator per Response Evaluation Criteria in Solid Tumours (RECIST v1.1)
  • Objective Response Rate (ORR) as determined by investigator per Response Evaluation Criteria in Solid Tumours (RECIST v1.1)
  • Overall Survival (OS)
  • Duration of Response (DOR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumours (RECIST v1.1)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society